Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists
[Display omitted] The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally re...
Gespeichert in:
Veröffentlicht in: | Biochemical pharmacology 2023-05, Vol.211, p.115485-115485, Article 115485 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 115485 |
---|---|
container_issue | |
container_start_page | 115485 |
container_title | Biochemical pharmacology |
container_volume | 211 |
creator | Billard, Etienne Hébert, Terence E. Chatenet, David |
description | [Display omitted]
The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally related hormones, which exert common and divergent effects, are thought to play specific biological roles. In recent years, we have characterized an analog termed urocontrin A (UCA), i.e. [Pep4]URP, which is capable of discriminating the effects of UII from URP. Such an action could allow the delineation of the respective functions of these two endogenous ligands. In an effort to define the molecular determinants involved in this behavior and to improve the pharmacological profile of UCA, we introduced modifications from urantide, considered for some time as a lead compound for the development of UT antagonists, into UCA and assessed the binding, contractile activity and G protein signaling of these newly developed compounds. Our results show that UCA and its derivatives exert probe-dependent effects on UT antagonism, and we have further identified [Pen2, Pep4]URP as a Gq biased ligand with an insurmountable antagonism in our aortic ring contraction assay. |
doi_str_mv | 10.1016/j.bcp.2023.115485 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2785197136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000629522300076X</els_id><sourcerecordid>2785197136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-5314eb4b688b1eb180bae7972cfe9a172e56beff5cad24a7769e4b10527562283</originalsourceid><addsrcrecordid>eNp9kM1vFCEYh4nR2LXtH-DFcPSyKzDDx8RT07S1SRMveibAvFPZMDACU13_etls9djT-5Hn_QUehN5TsqOEik_7nXXLjhHW7SjlveKv0IYq2W3ZINRrtCGEiNZzdobelbI_jkrQt-isE0oNfS826M_N7yWkbKpPEacJ1x-A15xcijX7iK9wcWaaUhjxwUMYC47w6whUiMVHyI_e4XIoFWZsQkityW0zp3ENpqaMTRyxS_MC1Vf_BG2u5jFFX2q5QG8mEwpcPtdz9P325tv1l-3D17v766uHret4V7e8oz3Y3rYnWwqWKmINyEEyN8FgqGTAhYVp4s6MrDdSigF6SwlnkgvGVHeOPp5yl5x-rlCqnn1xEIKJkNaimVScDpJ2oqH0hLqcSskw6SX72eSDpkQfleu9bsr1Ubk-KW83H57jVzvD-P_in-MGfD4B0D755CHr4jxEB6PP4Koek38h_i_KapSs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785197136</pqid></control><display><type>article</type><title>Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Billard, Etienne ; Hébert, Terence E. ; Chatenet, David</creator><creatorcontrib>Billard, Etienne ; Hébert, Terence E. ; Chatenet, David</creatorcontrib><description>[Display omitted]
The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally related hormones, which exert common and divergent effects, are thought to play specific biological roles. In recent years, we have characterized an analog termed urocontrin A (UCA), i.e. [Pep4]URP, which is capable of discriminating the effects of UII from URP. Such an action could allow the delineation of the respective functions of these two endogenous ligands. In an effort to define the molecular determinants involved in this behavior and to improve the pharmacological profile of UCA, we introduced modifications from urantide, considered for some time as a lead compound for the development of UT antagonists, into UCA and assessed the binding, contractile activity and G protein signaling of these newly developed compounds. Our results show that UCA and its derivatives exert probe-dependent effects on UT antagonism, and we have further identified [Pen2, Pep4]URP as a Gq biased ligand with an insurmountable antagonism in our aortic ring contraction assay.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2023.115485</identifier><identifier>PMID: 36889446</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Aortic ring bioassay ; Biased agonism ; BRET-based biosensor ; Human urotensin II receptor ; Ligands ; Peptide Hormones - chemistry ; Peptide Hormones - metabolism ; Peptide Hormones - pharmacology ; Probe-dependent action ; Receptors, G-Protein-Coupled - metabolism ; Signal Transduction ; Urantide ; Urocontrin A ; Urotensin II-related peptide ; Urotensins - metabolism ; Urotensins - pharmacology</subject><ispartof>Biochemical pharmacology, 2023-05, Vol.211, p.115485-115485, Article 115485</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-5314eb4b688b1eb180bae7972cfe9a172e56beff5cad24a7769e4b10527562283</citedby><cites>FETCH-LOGICAL-c353t-5314eb4b688b1eb180bae7972cfe9a172e56beff5cad24a7769e4b10527562283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bcp.2023.115485$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36889446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Billard, Etienne</creatorcontrib><creatorcontrib>Hébert, Terence E.</creatorcontrib><creatorcontrib>Chatenet, David</creatorcontrib><title>Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>[Display omitted]
The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally related hormones, which exert common and divergent effects, are thought to play specific biological roles. In recent years, we have characterized an analog termed urocontrin A (UCA), i.e. [Pep4]URP, which is capable of discriminating the effects of UII from URP. Such an action could allow the delineation of the respective functions of these two endogenous ligands. In an effort to define the molecular determinants involved in this behavior and to improve the pharmacological profile of UCA, we introduced modifications from urantide, considered for some time as a lead compound for the development of UT antagonists, into UCA and assessed the binding, contractile activity and G protein signaling of these newly developed compounds. Our results show that UCA and its derivatives exert probe-dependent effects on UT antagonism, and we have further identified [Pen2, Pep4]URP as a Gq biased ligand with an insurmountable antagonism in our aortic ring contraction assay.</description><subject>Aortic ring bioassay</subject><subject>Biased agonism</subject><subject>BRET-based biosensor</subject><subject>Human urotensin II receptor</subject><subject>Ligands</subject><subject>Peptide Hormones - chemistry</subject><subject>Peptide Hormones - metabolism</subject><subject>Peptide Hormones - pharmacology</subject><subject>Probe-dependent action</subject><subject>Receptors, G-Protein-Coupled - metabolism</subject><subject>Signal Transduction</subject><subject>Urantide</subject><subject>Urocontrin A</subject><subject>Urotensin II-related peptide</subject><subject>Urotensins - metabolism</subject><subject>Urotensins - pharmacology</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1vFCEYh4nR2LXtH-DFcPSyKzDDx8RT07S1SRMveibAvFPZMDACU13_etls9djT-5Hn_QUehN5TsqOEik_7nXXLjhHW7SjlveKv0IYq2W3ZINRrtCGEiNZzdobelbI_jkrQt-isE0oNfS826M_N7yWkbKpPEacJ1x-A15xcijX7iK9wcWaaUhjxwUMYC47w6whUiMVHyI_e4XIoFWZsQkityW0zp3ENpqaMTRyxS_MC1Vf_BG2u5jFFX2q5QG8mEwpcPtdz9P325tv1l-3D17v766uHret4V7e8oz3Y3rYnWwqWKmINyEEyN8FgqGTAhYVp4s6MrDdSigF6SwlnkgvGVHeOPp5yl5x-rlCqnn1xEIKJkNaimVScDpJ2oqH0hLqcSskw6SX72eSDpkQfleu9bsr1Ubk-KW83H57jVzvD-P_in-MGfD4B0D755CHr4jxEB6PP4Koek38h_i_KapSs</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Billard, Etienne</creator><creator>Hébert, Terence E.</creator><creator>Chatenet, David</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202305</creationdate><title>Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists</title><author>Billard, Etienne ; Hébert, Terence E. ; Chatenet, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-5314eb4b688b1eb180bae7972cfe9a172e56beff5cad24a7769e4b10527562283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aortic ring bioassay</topic><topic>Biased agonism</topic><topic>BRET-based biosensor</topic><topic>Human urotensin II receptor</topic><topic>Ligands</topic><topic>Peptide Hormones - chemistry</topic><topic>Peptide Hormones - metabolism</topic><topic>Peptide Hormones - pharmacology</topic><topic>Probe-dependent action</topic><topic>Receptors, G-Protein-Coupled - metabolism</topic><topic>Signal Transduction</topic><topic>Urantide</topic><topic>Urocontrin A</topic><topic>Urotensin II-related peptide</topic><topic>Urotensins - metabolism</topic><topic>Urotensins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Billard, Etienne</creatorcontrib><creatorcontrib>Hébert, Terence E.</creatorcontrib><creatorcontrib>Chatenet, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Billard, Etienne</au><au>Hébert, Terence E.</au><au>Chatenet, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>211</volume><spage>115485</spage><epage>115485</epage><pages>115485-115485</pages><artnum>115485</artnum><issn>0006-2952</issn><eissn>1873-2968</eissn><abstract>[Display omitted]
The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally related hormones, which exert common and divergent effects, are thought to play specific biological roles. In recent years, we have characterized an analog termed urocontrin A (UCA), i.e. [Pep4]URP, which is capable of discriminating the effects of UII from URP. Such an action could allow the delineation of the respective functions of these two endogenous ligands. In an effort to define the molecular determinants involved in this behavior and to improve the pharmacological profile of UCA, we introduced modifications from urantide, considered for some time as a lead compound for the development of UT antagonists, into UCA and assessed the binding, contractile activity and G protein signaling of these newly developed compounds. Our results show that UCA and its derivatives exert probe-dependent effects on UT antagonism, and we have further identified [Pen2, Pep4]URP as a Gq biased ligand with an insurmountable antagonism in our aortic ring contraction assay.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>36889446</pmid><doi>10.1016/j.bcp.2023.115485</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 2023-05, Vol.211, p.115485-115485, Article 115485 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_proquest_miscellaneous_2785197136 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Aortic ring bioassay Biased agonism BRET-based biosensor Human urotensin II receptor Ligands Peptide Hormones - chemistry Peptide Hormones - metabolism Peptide Hormones - pharmacology Probe-dependent action Receptors, G-Protein-Coupled - metabolism Signal Transduction Urantide Urocontrin A Urotensin II-related peptide Urotensins - metabolism Urotensins - pharmacology |
title | Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A20%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploration%20of%20the%20urocontrin%20A%20scaffold%20yields%20new%20urotensinergic%20system%20allosteric%20modulator%20and%20competitive%20antagonists&rft.jtitle=Biochemical%20pharmacology&rft.au=Billard,%20Etienne&rft.date=2023-05&rft.volume=211&rft.spage=115485&rft.epage=115485&rft.pages=115485-115485&rft.artnum=115485&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2023.115485&rft_dat=%3Cproquest_cross%3E2785197136%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785197136&rft_id=info:pmid/36889446&rft_els_id=S000629522300076X&rfr_iscdi=true |